NASDAQ:ACHV - Nasdaq - US0044685008 - Common Stock - Currency: USD
3.17
-0.05 (-1.55%)
The current stock price of ACHV is 3.17 USD. In the past month the price increased by 5.67%. In the past year, price decreased by -19.95%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 22 full-time employees. The firm is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. The company is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.
ACHIEVE LIFE SCIENCES INC
22722 29Th Dr. Se, Suite 100
Seattle WASHINGTON V6E 4H1 US
CEO: John Bencich
Employees: 22
Company Website: http://achievelifesciences.com/
Investor Relations: http://ir.oncogenex.com/index.cfm
Phone: 14256861500
The current stock price of ACHV is 3.17 USD. The price decreased by -1.55% in the last trading session.
The exchange symbol of ACHIEVE LIFE SCIENCES INC is ACHV and it is listed on the Nasdaq exchange.
ACHV stock is listed on the Nasdaq exchange.
13 analysts have analysed ACHV and the average price target is 16.32 USD. This implies a price increase of 414.83% is expected in the next year compared to the current price of 3.17. Check the ACHIEVE LIFE SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ACHIEVE LIFE SCIENCES INC (ACHV) has a market capitalization of 109.02M USD. This makes ACHV a Micro Cap stock.
ACHIEVE LIFE SCIENCES INC (ACHV) currently has 22 employees.
ACHIEVE LIFE SCIENCES INC (ACHV) has a resistance level at 3.19. Check the full technical report for a detailed analysis of ACHV support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ACHV does not pay a dividend.
ACHIEVE LIFE SCIENCES INC (ACHV) will report earnings on 2025-03-13, after the market close.
ACHIEVE LIFE SCIENCES INC (ACHV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.13).
The outstanding short interest for ACHIEVE LIFE SCIENCES INC (ACHV) is 9.35% of its float. Check the ownership tab for more information on the ACHV short interest.
ChartMill assigns a technical rating of 1 / 10 to ACHV. When comparing the yearly performance of all stocks, ACHV is a bad performer in the overall market: 86.78% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to ACHV. Both the profitability and financial health of ACHV have multiple concerns.
Over the last trailing twelve months ACHV reported a non-GAAP Earnings per Share(EPS) of -1.13. The EPS increased by 46.19% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -68.75% | ||
ROE | -104.99% | ||
Debt/Equity | 0.31 |
ChartMill assigns a Buy % Consensus number of 85% to ACHV. The Buy consensus is the average rating of analysts ratings from 13 analysts.